2'-Acetylacteoside

2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease^[1][2][3][4]. In Vitro:2'-Acetylacteoside (10^-7-10^-5 mol/L; 0.5 h, 24 h, 6 days) inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells and down-regulates the expression of key proteins in the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].
2'-Acetylacteoside binds to Akt3 protein in cultured adult SVZ-derived NSCs, protecting it from protease degradation^[2].
2'-Acetylacteoside (5-40 μM; 24 h) promotes proliferation of OGD/R-treated adult SVZ-derived NSCs^[2].
2'-Acetylacteoside (10 μM; 24 h) enhances the proliferation of OGD/R-treated adult SVZ-derived NSCs in vitro, as shown by a significant increase in EdU-positive cells^[2].
2'-Acetylacteoside (10 μM) promotes differentiation of OGD/R-treated adult SVZ-derived NSCs into immature neurons (DCX-positive) in vitro, without affecting gliogenesis^[2].
2'-Acetylacteoside (10 μM) promotes proliferation and neurogenesis of OGD/R-treated adult SVZ-derived NSCs in vitro via activation of the PI3K/Akt pathway, as shown by increased p-Akt, p-CREB, DCX, and NeuN expression^[2].
2'-Acetylacteoside alters gene expression in OGD/R-treated adult SVZ-derived NSCs in vitro, with significant enrichment of differentially expressed genes in the PI3K/Akt signaling pathway, and up-regulates neurogenesis-related genes including VEGFα, Errb4, Col1a1, and Igfbp5^[2].
2'-Acetylacteoside potently inhibited purified MAO-B enzyme in vitro with an IC₅₀ of 17.71 μM and acted as a reversible mixed inhibitor with high affinity for free MAO-B (Ki = 13.81 μM)^[3].
2'-Acetylacteoside (25-100 μM) scavenges superoxide radicals in a concentration-dependent manner in a cell-free in vitro system^[4]. In Vivo:2'-Acetylacteoside (2'-AA) (10-40 mg/kg/day; p.o.; daily; 12 weeks) exhibits significant anti-osteoporotic activity in ovariectomized mice, all doses improving trabecular bone microarchitecture and biomechanical strength via inhibition of the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].